Introduction: Metrics and Domains Measured in SLE

Updating the core domains set in Systemic Lupus Erythematosus: Work planned by the Systemic Lupus Erythematosus OMERACT working group

“…Systemic Lupus Erythematosus (SLE) has a significant impact on health-related quality of life (HRQoL) on patients. 1,2 Interventions to improve SLE patient HRQoL are assessed through randomized controlled trials (RCTs) and longitudinal studies (LOSs). Having standardized measurement metrics is essential to achieve valid results, improved communication, understanding, and dissemination of results.…”

“…The benefits of a CDS include, but are not limited to, standardizing outcome measure reporting and methods, better informing clinical guidelines, better communication and sharing of results, preventing duplicate research, incorporating meaningful outcome measures to patients, and guiding regulatory processes. 1 The previous CDS for SLE was developed in 1998 by the OMERACT SLE Working Group and contained 5 domains; disease activity, damage, Health-Related Quality of Life (HRQoL), adverse events, and economic costs. Since then, several novel pertinent domains have been identified and new instruments have been developed, thus there is an unmet need to update the SLE CDS and the instruments for each domain.…”

“…Since then, several novel pertinent domains have been identified and new instruments have been developed, thus there is an unmet need to update the SLE CDS and the instruments for each domain. 1 Consensus on instruments was not achieved in 1998 after the development of OMERACT SLE CDS. RCTs and LOSs of SLE are steadily increasing with SLE medication approvals over the last decade such as Belimumab, and more recently Anifrolumab, Voclosporin, and Belimumab in Lupus Nephritis.…”